REDWOOD CITY, Calif.,
Feb. 5, 2014 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that Richard King, President and CEO will be
presenting a Company update at three upcoming investor
conferences. Details of the three events are as follows:
BIO CEO & Investor
Conference
Date: Tuesday,
February 11, 2014
Location: Waldorf Astoria in New
York, NY
Presentation Time: 9:00 am ET, 6:00 am
PT
2014 RBC Capital Markets' Global Healthcare
Conference
Date: Wednesday,
February 26, 2014
Location: The New York Palace Hotel in New York, NY
Presentation Time: 10:00 am ET,
7:00 am PT
Cowen and Company 34th Annual Healthcare
Conference
Date: Tuesday, March
4, 2014
Location: The Boston Marriott Copley Place in Boston, MA
Presentation Time: 8:40 am ET,
5:40 am PT
All three presentations will be webcast live and can be accessed
through the Investors page at www.acelrx.com. For those not
available to listen to the live broadcast, a replay of the
presentations will be archived for 90 days and available through
the Investors page on www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for the treatment of acute and breakthrough pain. AcelRx's lead
product candidate, Zalviso™, is designed to solve the problems
associated with post-operative intravenous patient-controlled
analgesia which has been shown to cause harm to patients following
surgery because of the side effects of morphine, the invasive IV
route of delivery and the complexity of infusion pumps. AcelRx has
announced positive results from each of the three completed Phase 3
clinical trials for Zalviso, and has submitted an NDA to the FDA
seeking approval for Zalviso in the treatment of moderate-to-severe
acute pain in adult patients in the hospital setting. AcelRx
has also announced positive top-line results for a Phase 2 trial
for ARX-04, a product candidate for the treatment of
moderate-to-severe acute pain in a medically supervised setting,
funded through a grant from the U.S. Army Medical Research and
Materiel Command. The company has two additional pain
treatment product candidates, ARX-02 and ARX-03, which have
completed Phase 2 clinical development. For additional
information about AcelRx's clinical programs, please visit
www.acelrx.com
Forward Looking Statements
This press release
contains forward-looking statements, including, but not limited to,
statements related to submission of the NDA for Zalviso,
planned or anticipated future clinical development of AcelRx
Pharmaceuticals' product candidates, and the therapeutic potential
of Zalviso and the anticipated timing, therapeutic and commercial
potential of other AcelRx Pharmaceuticals' product
candidates. These forward-looking statements are based on
AcelRx Pharmaceuticals' current expectations and inherently involve
significant risks and uncertainties. AcelRx Pharmaceuticals'
actual results and the timing of events could differ materially
from those anticipated in such forward-looking statements as a
result of these risks and uncertainties, which include, without
limitation, risks related to: AcelRx's ability to receive
regulatory approval for Zalviso; any delays or inability to obtain
and maintain regulatory approval of its product candidates,
including Zalviso, in the United States and Europe;
the success, cost and timing of AcelRx Pharmaceuticals' product
development activities and clinical trials; the market potential
for its product candidates; and other risks detailed in the "Risk
Factors" and elsewhere in AcelRx's U.S. Securities and Exchange
Commission filings and reports, including its Quarterly Report on
Form 10-Q filed with the SEC on November 5,
2013. AcelRx undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of
new information, future events or changes in its expectations.
(Logo:
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)
SOURCE AcelRx Pharmaceuticals, Inc.